#2502. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom

November 2026publication date
Proposal available till 30-05-2025
4 total number of authors per manuscript4500 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Health Policy;
Economics and Econometrics;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
1350 $1200 $1050 $900 $
Contract №2502.1 Contract №2502.2 Contract №2502.3 Contract №2502.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
The article conducted a budget impact analysis to assess the financial implications of implementing the CT-P13 SC over a 5-year period. The methodology is based on a prevalence budget impact model that includes epidemiological data, data on administrative costs and data on market share. The results show that, compared to the “no world” scenario, the implementation of the CT-P13 SC resulted in cost savings in the UK of £ 69.3 million over a 5-year period.
Keywords:
rheumatoid arthritis; subcutaneous infliximab; budget

Contacts :
0